Previous 10 | Next 10 |
Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, ...
Cyclacel Pharmaceuticals (NASDAQ: CYCC ) initiated with Buy rating and $8 (1173% upside) price target at Roth Capital Partners. More news on: Cyclacel Pharmaceuticals, Inc., Dicerna Pharmaceuticals, Inc., Fate Therapeutics, Inc., Healthcare stocks news, , Stocks on the move, Read more ...
— Clinical Proof-of-Concept Data Expected in Fourth Quarter of 2019 — Dicerna Pharmaceuticals, Inc . (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today ...
Dicerna Pharmaceuticals, Inc. (DRNA) Q1 2019 Earnings Conference Call May 09, 2019, 16:30 ET Company Participants Kendra Packard - IR Douglas Fambrough - Co-Founder, CEO, President & Director John Green - CFO Ralf Rosskamp - Chief Medical Officer Conference Call Particip...
Dicerna Pharmaceuticals (NASDAQ: DRNA ): Q1 GAAP EPS of -$0.38 misses by $0.16 . More news on: Dicerna Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
— Initiated Screening of Participants to Enroll in the PHYOX™2 Phase 2 Pivotal Trial of DCR-PHXC for the Treatment of Primary Hyperoxaluria (PH) and Announced Updated Data from Ongoing PHYOX1 Phase 1 of DCR-PHXC – — Dosed First Healthy Volunteer in Phase 1 C...
Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its first quarter 2019 financial results af...
– Update Reflects Alignment with FDA on Path to Full Approval for Treatment of PH1 and Discussions Now Focusing on Appropriate Endpoints for PH2 and PH3 – Dicerna™ Pharmaceuticals, Inc. (Nasdaq:DRNA) (the “Company” or “Dicerna”), a le...
Novartis's 8.7 billion bet Last year Novartis ( NVS ) made waves by acquiring the gene therapy company AveXis for an astounding 8.7 billion dollars , setting in motion a rush of additional buyouts in this therapeutic space including Spark Therapeutics (4.8 billion) and Nightstar Therapeu...
Even as Alnylam ( ALNY ) works toward its second commercial drug filing, questions remain about the safety and efficacy of givosiran, not to mention the platform as a whole. But with good full Phase III data on givosiran and encouraging open-label extension data on lumasiran over the last fe...
News, Short Squeeze, Breakout and More Instantly...
Dicerna Pharmaceuticals Inc. Company Name:
DRNA Stock Symbol:
NASDAQ Market:
Dicerna Pharmaceuticals Inc. Website:
Novo Nordisk today announced that the acquisition of Dicerna Pharmaceuticals, Inc. (Dicerna; Nasdaq: DRNA), announced on 18 November 2021, has been completed. Following the expiration of Novo Nordisk’s cash tender offer for Dicerna, Novo Nordisk has today acquired all outstan...
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR”), in connection with Novo Nordisk’s cash tender offer for Dicerna expired at 11:59 p.m., Easter...
Direxion Launches mRNA ETF (MSGR) MSGR Offers Exposure to Rapidly Evolving mRNA Sector PR Newswire NEW YORK , Dec. 9, 2021 /PRNewswire/ -- Direxion announced today the launch of the Direxion mRNA ETF (Ticker: MSGR) . MSGR invests in companies ...